Skip to main content
Premium Trial:

Request an Annual Quote

EraGen Partners with Illumina to Develop Molecular Dx Assays

NEW YORK (GenomeWeb News) – EraGen Biosciences said today that it has formed a strategic partnership with Illumina to develop high-throughput, multiplexed clinical assays.

Under the agreement, EraGen, based in Madison, Wis., has non-exclusively licensed the use of Illumina's BeadXpress platform to develop and commercialize molecular-based, high-throughput, clinical assays using EraGen's MultiCode-PLx technology.

Meantime, Illumina has non-exclusively licensed EraGen's MultiCode-PLx technology for the life sciences, research, and clinical markets.

Financial terms of the agreement were not disclosed.

"Our newly formed relationship with Illumina further validates our MultiCode technology's versatile application in the development and commercialization of molecular-based assays for the clinical market," Irene Hrusovsky, president and CEO of EraGen, said in a statement.

EraGen's MultiCode technology detects RNA and DNA targets by combining multiplexed PCR with its ISO bases, which are structurally similar to standard nucleobases but have altered base-pairing specificity.

EraGen said that the pact is part of its strategy to continue expanding its commercial efforts in the molecular diagnostics market.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.